Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Aug 15;358(Pt 1):249–255. doi: 10.1042/0264-6021:3580249

Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.

V Di Marzo 1, D Melck 1, P Orlando 1, T Bisogno 1, O Zagoory 1, M Bifulco 1, Z Vogel 1, L De Petrocellis 1
PMCID: PMC1222054  PMID: 11485574

Abstract

Palmitoylethanolamide (PEA) has been shown to act in synergy with anandamide (arachidonoylethanolamide; AEA), an endogenous agonist of cannabinoid receptor type 1 (CB(1)). This synergistic effect was reduced by the CB(2) cannabinoid receptor antagonist SR144528, although PEA does not activate either CB(1) or CB(2) receptors. Here we show that PEA potently enhances the anti-proliferative effects of AEA on human breast cancer cells (HBCCs), in part by inhibiting the expression of fatty acid amide hydrolase (FAAH), the major enzyme catalysing AEA degradation. PEA (1-10 microM) enhanced in a dose-related manner the inhibitory effect of AEA on both basal and nerve growth factor (NGF)-induced HBCC proliferation, without inducing any cytostatic effect by itself. PEA (5 microM) decreased the IC(50) values for AEA inhibitory effects by 3-6-fold. This effect was not blocked by the CB(2) receptor antagonist SR144528, and was not mimicked by a selective agonist of CB(2) receptors. PEA enhanced AEA-evoked inhibition of the expression of NGF Trk receptors, which underlies the anti-proliferative effect of the endocannabinoid on NGF-stimulated MCF-7 cells. The effect of PEA was due in part to inhibition of AEA degradation, since treatment of MCF-7 cells with 5 microM PEA caused a approximately 30-40% down-regulation of FAAH expression and activity. However, PEA also enhanced the cytostatic effect of the cannabinoid receptor agonist HU-210, although less potently than with AEA. PEA did not modify the affinity of ligands for CB(1) or CB(2) receptors, and neither did it alter the CB(1)/CB(2)-mediated inhibitory effect of AEA on adenylate cyclase type V, nor the expression of CB(1) and CB(2) receptors in MCF-7 cells. We suggest that long-term PEA treatment of cells may positively affect the pharmacological activity of AEA, in part by inhibiting FAAH expression.

Full Text

The Full Text of this article is available as a PDF (154.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aceto M. D., Scates S. M., Razdan R. K., Martin B. R. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther. 1998 Nov;287(2):598–605. [PubMed] [Google Scholar]
  2. Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39(Spec No):C145–C147. doi: 10.1007/BF01972748. [DOI] [PubMed] [Google Scholar]
  3. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M. H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998 Jul 17;353(1):23–31. doi: 10.1016/s0014-2999(98)00392-6. [DOI] [PubMed] [Google Scholar]
  4. Bisogno T., Katayama K., Melck D., Ueda N., De Petrocellis L., Yamamoto S., Di Marzo V. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem. 1998 Jun 15;254(3):634–642. doi: 10.1046/j.1432-1327.1998.2540634.x. [DOI] [PubMed] [Google Scholar]
  5. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997 Feb 7;272(6):3315–3323. doi: 10.1074/jbc.272.6.3315. [DOI] [PubMed] [Google Scholar]
  6. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998 Jul 16;394(6690):277–281. doi: 10.1038/28393. [DOI] [PubMed] [Google Scholar]
  7. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996 Nov 7;384(6604):83–87. doi: 10.1038/384083a0. [DOI] [PubMed] [Google Scholar]
  8. De Petrocellis L., Bisogno T., Davis J. B., Pertwee R. G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 2000 Oct 13;483(1):52–56. doi: 10.1016/s0014-5793(00)02082-2. [DOI] [PubMed] [Google Scholar]
  9. De Petrocellis L., Melck D., Bisogno T., Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids. 2000 Nov;108(1-2):191–209. doi: 10.1016/s0009-3084(00)00196-1. [DOI] [PubMed] [Google Scholar]
  10. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8375–8380. doi: 10.1073/pnas.95.14.8375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992 Dec 18;258(5090):1946–1949. doi: 10.1126/science.1470919. [DOI] [PubMed] [Google Scholar]
  12. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994 Dec 15;372(6507):686–691. doi: 10.1038/372686a0. [DOI] [PubMed] [Google Scholar]
  13. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376–3380. doi: 10.1073/pnas.92.8.3376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Galve-Roperh I., Sánchez C., Cortés M. L., Gómez del Pulgar T., Izquierdo M., Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000 Mar;6(3):313–319. doi: 10.1038/73171. [DOI] [PubMed] [Google Scholar]
  15. Griffin G., Tao Q., Abood M. E. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther. 2000 Mar;292(3):886–894. [PubMed] [Google Scholar]
  16. Jaggar S. I., Hasnie F. S., Sellaturay S., Rice A. S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998 May;76(1-2):189–199. doi: 10.1016/s0304-3959(98)00041-4. [DOI] [PubMed] [Google Scholar]
  17. Kacker A., April M., Ward R. F. Use of potassium titanyl phosphate (KTP) laser in management of subglottic hemangiomas. Int J Pediatr Otorhinolaryngol. 2001 May 31;59(1):15–21. doi: 10.1016/s0165-5876(01)00451-7. [DOI] [PubMed] [Google Scholar]
  18. Katayama K., Ueda N., Katoh I., Yamamoto S. Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim Biophys Acta. 1999 Sep 22;1440(2-3):205–214. doi: 10.1016/s1388-1981(99)00124-9. [DOI] [PubMed] [Google Scholar]
  19. Lambert D. M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999 Aug;6(8):757–773. [PubMed] [Google Scholar]
  20. Lambert D. M., DiPaolo F. G., Sonveaux P., Kanyonyo M., Govaerts S. J., Hermans E., Bueb J., Delzenne N. M., Tschirhart E. J. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta. 1999 Sep 22;1440(2-3):266–274. doi: 10.1016/s1388-1981(99)00132-8. [DOI] [PubMed] [Google Scholar]
  21. Maccarrone M., Fiorucci L., Erba F., Bari M., Finazzi-Agrò A., Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett. 2000 Feb 25;468(2-3):176–180. doi: 10.1016/s0014-5793(00)01223-0. [DOI] [PubMed] [Google Scholar]
  22. Maccarrone M., Salvati S., Bari M., Finazzi-Agró Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun. 2000 Nov 30;278(3):576–583. doi: 10.1006/bbrc.2000.3869. [DOI] [PubMed] [Google Scholar]
  23. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 Aug 9;346(6284):561–564. doi: 10.1038/346561a0. [DOI] [PubMed] [Google Scholar]
  24. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996 Apr 11;300(3):227–236. doi: 10.1016/0014-2999(96)00015-5. [DOI] [PubMed] [Google Scholar]
  25. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun. 1999 Aug 19;262(1):275–284. doi: 10.1006/bbrc.1999.1105. [DOI] [PubMed] [Google Scholar]
  26. Melck D., De Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M., Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000 Jan;141(1):118–126. doi: 10.1210/endo.141.1.7239. [DOI] [PubMed] [Google Scholar]
  27. Melck D., Rueda D., Galve-Roperh I., De Petrocellis L., Guzmán M., Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 1999 Dec 17;463(3):235–240. doi: 10.1016/s0014-5793(99)01639-7. [DOI] [PubMed] [Google Scholar]
  28. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 Sep 2;365(6441):61–65. doi: 10.1038/365061a0. [DOI] [PubMed] [Google Scholar]
  29. Rhee M. H., Bayewitch M., Avidor-Reiss T., Levy R., Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem. 1998 Oct;71(4):1525–1534. doi: 10.1046/j.1471-4159.1998.71041525.x. [DOI] [PubMed] [Google Scholar]
  30. Ross R. A., Brockie H. C., Pertwee R. G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol. 2000 Aug 4;401(2):121–130. doi: 10.1016/s0014-2999(00)00437-4. [DOI] [PubMed] [Google Scholar]
  31. Schmid H. H., Schmid P. C., Natarajan V. N-acylated glycerophospholipids and their derivatives. Prog Lipid Res. 1990;29(1):1–43. doi: 10.1016/0163-7827(90)90004-5. [DOI] [PubMed] [Google Scholar]
  32. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem. 1997 Feb 28;40(5):659–667. doi: 10.1021/jm960752x. [DOI] [PubMed] [Google Scholar]
  33. Tiger G., Stenström A., Fowler C. J. Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. Biochem Pharmacol. 2000 Mar 15;59(6):647–653. doi: 10.1016/s0006-2952(99)00373-1. [DOI] [PubMed] [Google Scholar]
  34. Ueda N., Puffenbarger R. A., Yamamoto S., Deutsch D. G. The fatty acid amide hydrolase (FAAH). Chem Phys Lipids. 2000 Nov;108(1-2):107–121. doi: 10.1016/s0009-3084(00)00190-0. [DOI] [PubMed] [Google Scholar]
  35. Ueda N., Yamanaka K., Terasawa Y., Yamamoto S. An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett. 1999 Jul 9;454(3):267–270. doi: 10.1016/s0014-5793(99)00820-0. [DOI] [PubMed] [Google Scholar]
  36. Wallach J., Droste M., Kluxen F. W., Pfeuffer T., Frank R. Molecular cloning and expression of a novel type V adenylyl cyclase from rabbit myocardium. FEBS Lett. 1994 Feb 7;338(3):257–263. doi: 10.1016/0014-5793(94)80279-3. [DOI] [PubMed] [Google Scholar]
  37. van der Stelt M., Paoletti A. M., Maccarrone M., Nieuwenhuizen W. F., Bagetta G., Veldink G. A., Finazzi Agrò A., Vliegenthart J. F. The effect of hydroxylation of linoleoyl amides on their cannabinomimetic properties. FEBS Lett. 1997 Oct 6;415(3):313–316. doi: 10.1016/s0014-5793(97)01148-4. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES